We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. Fecal dipeptidyl peptidase-4 may be used as a ...

SGLT2 inhibitors showed significantly improved mortality benefits compared with DPP-4 inhibitors in patients with diabetic kidney disease (DKD) in a large target trial emulation study that adds ...

In September, Indian drug manufacturer Alembic received a tentative nod from the US Food and Drug Administration (FDA) to manufacture generic alogliptin as well as the alogliptin/metformin fixed-drug ...

Last year, an FDA advisory panel called for an updated label for saxagliptin, but the agency is still gathering information. An analysis of claims data found no association between the use of DPP-4 ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. Dipeptidyl peptidase-4 inhibition to treat type 2 ...

DPP-4 exists as a membrane-bound form, widely expressed and enzymatically active on numerous cell types and different vascular beds... ...as well as a soluble form ...

Researchers found that the rate difference of depression was 3.48 per 1000 person-years between GLP-1 RA users and SGLT-2i users. HealthDay News — For older adults with type 2 diabetes (T2D), use of ...

The results suggest that dipeptidyl peptidase-4 (DDP-4) inhibitors, which are widely prescribed in Germany, are not a cost-effective option despite lower drug pricing compared with empagliflozin.

Among people with type 2 diabetes, new treatment with a dipeptidyl peptidase 4 (DPP-4) inhibitor was linked with higher risk of a rare blistering skin condition, researchers reported. Compared with ...

Across a broad swath of patients, short-term use of a sodium-glucose cotransporter 2 (SGLT2) inhibitor appears to reduce the risk of major adverse cardiovascular events, most notably cardiovascular ...